Parabilis Medicines (NASDAQ:PBLS) Shares Climb 9.1% - Still a Buy?

Key Points

• Parabilis Medicines shares rose 9.1% to $29.73, though trading volume was 87% below the stock’s average daily volume.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $41.25, implying potential upside.
• The clinical-stage biotech reported a significant quarterly EPS loss of $2.32 versus the $0.16 consensus estimate, while several major institutional investors—including Alphabet and Regeneron—recently acquired positions.

Parabilis Medicines, Inc. (NASDAQ:PBLS - Get Free Report) traded up 9.1% during mid-day trading on Tuesday. The stock traded as high as $29.73 and last traded at $29.73. 108,796 shares were traded during trading, a decline of 87% from the average daily volume of 815,535 shares. The stock had previously closed at $27.25.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PBLS. Evercore assumed coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set an "outperform" rating on the stock. Bank of America assumed coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They issued a "buy" rating and a $45.00 target price for the company. Lifesci Capital raised shares of Parabilis Medicines to a "strong-buy" rating in a research note on Monday, July 6th. Zacks Research raised shares of Parabilis Medicines to a "hold" rating in a report on Tuesday, July 7th. Finally, HC Wainwright started coverage on Parabilis Medicines in a report on Thursday, October 22nd. They set a "buy" rating and a $40.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.25.

Parabilis Medicines Price Performance

The firm has a market cap of $3.57 billion and a P/E ratio of -13.55. The business's 50-day moving average price is $32.72.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $0.15 million for the quarter. As a group, research analysts expect that Parabilis Medicines, Inc. will post -2.60 earnings per share for the current year.

Institutional Trading of Parabilis Medicines

A number of institutional investors have recently bought and sold shares of the business. ARCH Venture Management LLC acquired a new position in shares of Parabilis Medicines in the 2nd quarter valued at $175,517,789. venBio Partners LLC acquired a new stake in shares of Parabilis Medicines in the 2nd quarter valued at approximately $144,149,497. Alphabet Inc. bought a new position in Parabilis Medicines during the 2nd quarter worth approximately $134,647,000. Regeneron Pharmaceuticals Inc. bought a new position in Parabilis Medicines during the 2nd quarter worth approximately $114,042,000. Finally, Jupiter Topco LLC bought a new position in Parabilis Medicines during the 2nd quarter worth approximately $62,710,000.

Parabilis Medicines Company Profile

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.